$1.91 $0.01 (0.0%)

04:30 PM EDT on 05/20/19

Fortress Biotech, Inc. (NASDAQ:FBIO)

CAPS Rating: 2 out of 5

Current Price $1.91 Mkt Cap $108.5M
Open $1.89 P/E Ratio 0.00
Prev. Close $1.91 Div. (Yield) $0.00 (0.0%)
Daily Range $1.78 - $1.97 Volume 59,291
52-Wk Range $0.86 - $2.57 Avg. Daily Vol.

Caps

How do you think NASDAQ:FBIO will perform against the market?

Add Stock to CAPS Watchlist

All Players

37 Outperform
6 Underperform
 

All-Star Players

12 Outperform
5 Underperform
 

Wall Street

3 Outperform
0 Underperform
 

Top NASDAQ:FBIO Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

zzlangerhans (99.81)
Submitted March 05, 2015

As I write, it seems like the saga of Pharmacyclics has come to an end with a share price more than 100 fold higher than the lows in 2009. I was certainly a skeptic, but fortunately for my brokerage account and my CAPS score I turned it around before… More

zzlangerhans (99.81)
Submitted September 03, 2014

I hadn't looked at Coronado for a while but I was running my CAPS list and noticed my green thumb had a winning score. I decided to take a quick peek to figure out if I should harvest the gain or let it run. The first thing I noticed was that the… More

NASDAQ:FBIO VS S&P 500 (SPY)

NASDAQ:FBIO Summary

Recent Community Commentary

Read the most recent pitches from players about FBIO.

Recs

5
Member Avatar zzlangerhans (99.81) Submitted: 3/5/2015 12:55:37 AM : Outperform Start Price: $3.30 NASDAQ:FBIO Score: -77.26

As I write, it seems like the saga of Pharmacyclics has come to an end with a share price more than 100 fold higher than the lows in 2009. I was certainly a skeptic, but fortunately for my brokerage account and my CAPS score I turned it around before it was too late. What made Pharmacyclics such a sleeper? It was the persistence of the company in wasting remaining resources on Xyctrin after it was obvious to everyone that it was a failure, coupled with the spec crash that seemed as though it would wipe out dozens of biotech stocks. No one was really watching as management underwent a hostile takeover and a new anti-cancer compound advanced into clinical trials. That compound became Imbruvica and the rest is history. I learned from Pharmacyclics not to dismiss a company until I was sure there was nothing of value left in the pipe.

Coronado isn't a close parallel to Pharmacyclics, but I do think there are few eyes on the company right now as they reinvent themselves following the predictable failure of worm eggs to cure autoimmune diseases. After bottoming below 1.5 last year, the company has been restructuring themselves in a complex way. A new subsidiary called CB Acquisition Group was funded with a small IPO and will apparently be spun off. This morning Coronado announced the formation of another subsidiary to be called Checkpoint Therapeutics. Checkpoint will advance a portfolio of human IO-targeted mAb's developed by Wayne Marasco at Dana Farber. Checkpoint has collaborated with TG Therapeutics to develop the anti-PD-L1 and anti-GTR Ab programs in hematologic malignancies. TG Therapeutics is connected to Lindsay Rosenwald, the CEO of Coronado and a long-term player in biopharma venture financing.

What does all this mean? I think Rosenwald has bigger fish to fry than just dragging out his lifespan as CEO of Coronado. That salary is pocket change for him. There's clearly an attempt here to become a serious player in the IO field, which is one of the hottest areas in oncology. If they can pull it off, Coronado will be worth a lot more than the 150M cap they sport today. I made a rapid decision to buy 2000 shares in the premarket at 3.05 this morning and wished I had gone ahead with 20000 as the share price shot up over 3.6. In the end, I held my shares as the stock settled at 3.2 and I imagine the position will get substantially larger if the near-term price action doesn't indicate that I've been suckered.

Recs

0
Member Avatar JavaChipFool (78.07) Submitted: 2/5/2014 3:22:21 PM : Outperform Start Price: $2.45 NASDAQ:FBIO Score: -84.12

Biotech gamble, down but not out

Recs

0
Member Avatar fatmoneyrz (96.29) Submitted: 10/14/2013 2:19:27 PM : Outperform Start Price: $2.10 NASDAQ:FBIO Score: -75.48

Nice entry on nice little biotech with a solid pipeline and solid cash position.

Leaderboard

Find the members with the highest scoring picks in FBIO.

Score Leader

GatitoPeligroso

GatitoPeligroso (99.37) Score: +175.74

The Score Leader is the player with the highest score across all their picks in FBIO.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
rknapton 85.62 8/7/2013 Underperform 5Y $10.02 -80.94% +67.98% +148.91 2 Comments
ziggystraw 99.14 9/3/2014 Underperform 5Y $2.11 -9.48% +41.34% +50.82 0 Comment
pbtoau78 69.43 9/25/2014 Underperform 5Y $1.89 +1.06% +42.79% +41.73 0 Comment
mikefee 93.29 6/23/2014 Underperform 5Y $1.78 +7.30% +45.20% +37.90 0 Comment
portefeuille 98.19 4/29/2019 Outperform 5Y $1.76 +8.52% -3.17% +11.70 0 Comment
clangmead 20.72 4/29/2019 Outperform 5Y $1.76 +8.52% -3.17% +11.70 0 Comment
jesterjohn 93.43 3/5/2019 Underperform 3M $2.02 -5.45% +1.67% +7.11 0 Comment
Maddentycoon 31.48 2/19/2019 Outperform 3W $2.18 -12.39% +2.79% -15.18 0 Comment
Teknikscian 64.81 8/5/2014 Outperform 5Y $1.49 +28.19% +47.18% -18.99 0 Comment
evanspitzer 35.21 5/19/2014 Outperform 5Y $1.74 +9.77% +51.42% -41.65 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackBofASec 91.44 4/22/2013 Outperform NS $11.28 -83.07% +82.44% -165.50 0 Comment
TrackCanaccord 68.01 3/25/2013 Outperform NS $9.73 -81.81% +9.10% -90.91 10/15/2013 @ $1.77 0 Comment
TrackPiperJaff 85.87 3/1/2013 Outperform NS $8.13 -76.51% +88.10% -164.61 0 Comment
TrackRothCapital 71.74 1/22/2013 Outperform NS $6.73 -71.62% +91.60% -163.22 0 Comment
TrackOppenheimer 51.58 2/24/2012 Outperform NS $7.00 -61.00% +33.91% -94.91 1/3/2014 @ $2.73 0 Comment

Advertisement